Showing results (331-340 of 501) with videos related to
Sort By:
Pageof 51
European Urology|May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 TrialOliver Sartor, Theodore G Karrison, Howard M Sandler, et al.JCO Precision Oncology|January 31, 2025
Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Matthew R Smith, Fred Saad, et al.Prostate Cancer and Prostatic Diseases|January 11, 2022
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomicsPhilip Sutera, Kim Van Der Eecken, Amar U Kishan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null DiseaseNing Zhao, Shalini Chopra, Kai Trepka, et al.International Journal of Radiation Oncology, Biology, Physics|October 18, 2016
Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational StudyThomas M Pisansky, Shree Agrawal, Daniel A Hamstra, et al.European Urology|June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601William C Jackson, Ming Tang, Matthew J Schipper, et al.Medical Oncology (Northwood, London, England)|October 8, 2015
Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathologyMartin J Magers, Tianyu Zhan, Aaron M Udager, et al.Biorxiv : the Preprint Server for Biology|April 16, 2025
EcDNA-borne PVT1 fusion stabilizes oncogenic mRNAsHyerim Yi, Shu Zhang, Jason Swinderman, et al.Cell Stem Cell|March 15, 2016
CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCsMohammad A Mandegar, Nathaniel Huebsch, Ekaterina B Frolov, et al.Pageof 51